Shattuck lecture--cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities.

Tthe end of every century it is customary to reflect on the events of the past hundred years and to look toward the future, and in this lecture I should like to do this for cardiovascular disease. This is also an especially opportune time to comment on progress in cardiovascular disease, because both the National Heart, Lung, and Blood Institute and the American Heart Association are celebrating their golden anniversaries within the next 18 months. These two organizations have had the most profound influence on the development of research on cardiovascular disease during the 20th century. A bewildering amount of . . .

[1]  S. Vollset,et al.  Plasma homocysteine levels and mortality in patients with coronary artery disease. , 1997, The New England journal of medicine.

[2]  E. Gurfinkel,et al.  Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS pilot study , 1997, The Lancet.

[3]  S. Nattel,et al.  Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group. , 1997, The New England journal of medicine.

[4]  B. Davis,et al.  Prevention of Heart Failure by Antihypertensive Drug Treatment in Older Persons With Isolated Systolic Hypertension , 1997 .

[5]  J. Leavitt,et al.  Emergency Department Use of Aspirin in Patients with Possible Acute Myocardial Infarction , 1997, Annals of Internal Medicine.

[6]  R A Schatz,et al.  Catheter-based radiotherapy to inhibit restenosis after coronary stenting. , 1997, The New England journal of medicine.

[7]  Cristina Barlassina,et al.  Polymorphisms of α-adducin and salt sensitivity in patients with essential hypertension , 1997, The Lancet.

[8]  C A Beltrami,et al.  Apoptosis in the failing human heart. , 1997, The New England journal of medicine.

[9]  P. Ridker,et al.  Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. , 1997, The New England journal of medicine.

[10]  L. Goldman,et al.  The recent decline in mortality from coronary heart disease, 1980-1990. The effect of secular trends in risk factors and treatment. , 1997, JAMA.

[11]  L Goldman,et al.  Adverse Outcomes of Underuse of β-Blockers in Elderly Survivors of Acute Myocardial Infarction , 1997 .

[12]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[13]  P. Anversa,et al.  Necrotic and apoptotic myocyte cell death in the aging heart of Fischer 344 rats. , 1996, The American journal of physiology.

[14]  A. Glasebrook,et al.  Identification of an Estrogen Response Element Activated by Metabolites of 17β-Estradiol and Raloxifene , 1996, Science.

[15]  R. Lifton.  Molecular Genetics of Human Blood Pressure Variation , 1996, Science.

[16]  G. Gibbons,et al.  Molecular Therapies for Vascular Diseases , 1996, Science.

[17]  J. Breslow.  Mouse Models of Atherosclerosis , 1996, Science.

[18]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .

[19]  P. Anversa,et al.  Gender differences and aging: effects on the human heart. , 1995, Journal of the American College of Cardiology.

[20]  P Whelton,et al.  Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the health examination surveys, 1960 to 1991. , 1995, Hypertension.

[21]  N. Maeda,et al.  Gene targeting approaches to complex genetic diseases: atherosclerosis and essential hypertension. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Jason A. Lowry,et al.  Arterial gene therapy for therapeutic angiogenesis in patients with peripheral artery disease. , 1995, Circulation.

[23]  P. Libby.  Molecular bases of the acute coronary syndromes. , 1995, Circulation.

[24]  R. Matthews,et al.  A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase , 1995, Nature Genetics.

[25]  P. Ganz,et al.  Estrogen Improves Endothelium-Dependent, Flow-Mediated Vasodilation in Postmenopausal Women , 1994, Annals of Internal Medicine.

[26]  O. H. Bing.  Hypothesis: apoptosis may be a mechanism for the transition to heart failure with chronic pressure overload. , 1994, Journal of molecular and cellular cardiology.

[27]  R. Lefkowitz,et al.  Enhanced myocardial function in transgenic mice overexpressing the beta 2-adrenergic receptor. , 1994, Science.

[28]  Epic Investigators,et al.  Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. , 1994, The New England journal of medicine.

[29]  Walker,et al.  Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients , 1994 .

[30]  E. J. Brown,et al.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.

[31]  J. Loscalzo,et al.  Lipoprotein(a). A unique risk factor for atherothrombotic disease. , 1990, Arteriosclerosis.

[32]  R. Pokras.  Detailed diagnoses and procedures for patients discharged from short-stay hospitals. United States, 1985. , 1987, Vital and health statistics. Series 13, Data from the National Health Survey.

[33]  M. Brown,et al.  A receptor-mediated pathway for cholesterol homeostasis. , 1986, Science.

[34]  M. LeWinter,et al.  Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. , 1983, The New England journal of medicine.

[35]  E. Veys,et al.  HL-A AND INFECTIVE SACROILEITIS , 1974 .

[36]  W. Kannel,et al.  Factors of risk in the development of coronary heart disease--six year follow-up experience. The Framingham Study. , 1961, Annals of internal medicine.

[37]  W. B. Kouwenhoven,et al.  Closed chest defibrillation of the heart. , 1957, Surgery.

[38]  T. Dawber,et al.  Epidemiological approaches to heart disease: the Framingham Study. , 1951, American journal of public health and the nation's health.

[39]  J. Herrick.  CLINICAL FEATURES OF SUDDEN OBSTRUCTION OF THE CORONARY ARTERIES , 1912 .